{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T08:55:16Z","timestamp":1790326516701,"version":"4.1.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.msard.2023.104826","type":"journal-article","created":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T14:11:42Z","timestamp":1686406302000},"page":"104826","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["How to measure the treatment response in progressive multiple sclerosis: Current perspectives and limitations in clinical settings\u2019"],"prefix":"10.1016","volume":"76","author":[{"given":"L.","family":"Lorefice","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Mellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Fenu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Cocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2023.104826_bib0001","doi-asserted-by":"crossref","unstructured":"Amezcua L. Progressive multiple sclerosis. Continuum (Minneap Minn). 2022 Aug 1;28(4):1083\u20131103.","DOI":"10.1212\/CON.0000000000001157"},{"key":"10.1016\/j.msard.2023.104826_bib0002","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1477-7525-2-12","article-title":"Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease","volume":"2","author":"Atkinson","year":"2004","journal-title":"Health Qual. Life Outcomes"},{"issue":"3","key":"10.1016\/j.msard.2023.104826_bib0003","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1207\/s15327752jpa6703_13","article-title":"Comparison of beck depression inventories -IA and -II in psychiatric outpatients","volume":"67","author":"Beck","year":"1996","journal-title":"J. Pers. Assess."},{"issue":"5","key":"10.1016\/j.msard.2023.104826_bib0004","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1177\/1352458520936239","article-title":"Long-term effect of natalizumab in patients with RRMS: TYSTEN cohort","volume":"27","author":"Bigaut","year":"2021","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2023.104826_bib0005","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/brain\/awf025","article-title":"Brain atrophy in clinically early relapsing-remitting multiple sclerosis","volume":"125","author":"Chard","year":"2002","journal-title":"Brain"},{"issue":"Pt 3","key":"10.1016\/j.msard.2023.104826_bib0006","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/brain\/awl007","article-title":"Natural history of multiple sclerosis: a unifying concept","volume":"129","author":"Confavreux","year":"2006","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.msard.2023.104826_bib0007","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1177\/1352458520936214","article-title":"Patient reported outcomes and performance metrics at diagnosis of secondary progressive multiple sclerosis","volume":"27","author":"Conway","year":"2021","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.msard.2023.104826_bib0008","first-page":"527","article-title":"Progressive multiple sclerosis: from pathogenic mechanisms to treatment","volume":"140","author":"Correale","year":"2017","journal-title":"Brain."},{"key":"10.1016\/j.msard.2023.104826_bib0009","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.msard.2019.05.019","article-title":"Review: patient-reported outcomes in multiple sclerosis care","volume":"33","author":"D'Amico","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104826_bib0010","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40263-014-0140-z","article-title":"Clinical relevance of brain volume measures in multiple sclerosis","volume":"28","author":"De Stefano","year":"2014","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.msard.2023.104826_bib0011","first-page":"93","article-title":"Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis","volume":"87","author":"De Stefano","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"6","key":"10.1016\/j.msard.2023.104826_bib0012","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1007\/s00415-021-10901-2","article-title":"The no evidence of disease activity (NEDA) concept in MS: impact of spinal cord MRI","volume":"269","author":"Di Sabatino","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2023.104826_bib0013","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/B978-0-444-53485-9.00020-9","article-title":"Multiple sclerosis","volume":"135","author":"Filippi","year":"2016","journal-title":"Handb. Clin. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2023.104826_bib0014","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/ana.25808","article-title":"Identifying progression in multiple sclerosis: new perspectives","volume":"88","author":"Filippi","year":"2020","journal-title":"Ann. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2023.104826_bib0015","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/WCO.0000000000000572","article-title":"MRI in multiple sclerosis: what is changing?","volume":"31","author":"Filippi","year":"2018","journal-title":"Curr. Opin. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2023.104826_bib0016","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1093\/clinids\/18.Supplement_1.S79","article-title":"Measuring the functional impact of fatigue: initial validation of the fatigue impact scale","author":"Fisk","year":"1994","journal-title":"Clin. Infect. Dis."},{"issue":"4","key":"10.1016\/j.msard.2023.104826_bib0017","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/WCO.0000000000000572","article-title":"MRI in multiple sclerosis: what is changing?","volume":"31","author":"Fox","year":"2018","journal-title":"Curr. Opin. Neurol."},{"issue":"9","key":"10.1016\/j.msard.2023.104826_bib0018","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1177\/1352458517703193","article-title":"No evident disease activity\": the use of combined assessments in the management of patients with multiple sclerosis","volume":"23","author":"Giovannoni","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.104826_bib0019","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.msard.2017.07.011","article-title":"A brief history of NEDA","volume":"20","author":"Giovannoni","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2023.104826_bib0020","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S1474-4422(22)00184-3","article-title":"Ageing and multiple sclerosis","volume":"22","author":"Graves","year":"2023","journal-title":"Lancet Neurol."},{"issue":"Pt 5","key":"10.1016\/j.msard.2023.104826_bib0021","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/brain\/124.5.962","article-title":"The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure","volume":"124","author":"Hobart","year":"2001","journal-title":"Brain"},{"key":"10.1016\/j.msard.2023.104826_bib0022","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase study","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.msard.2023.104826_bib0023","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/ene.13339","article-title":"Patient-reported outcomes in multiple sclerosis: a systematic comparison of available measures","volume":"24","author":"Khurana","year":"2017","journal-title":"Eur. J. Neurol."},{"issue":"5","key":"10.1016\/j.msard.2023.104826_bib0024","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1212\/NXI.0000000000000279","article-title":"The topographical model of multiple sclerosis: a dynamic visualization of disease course","volume":"3","author":"Krieger","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2023.104826_bib0025","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1177\/1352458515594440","article-title":"A 10-year follow-up of the European multicenter trial of interferon beta-1b in secondary-progressive multiple sclerosis","volume":"22","author":"Kuhle","year":"2016","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.msard.2023.104826_bib0026","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1474-4422(22)00289-7","article-title":"Multiple sclerosis progression: time for a new mechanism-driven framework","volume":"22","author":"Kuhlmann","year":"2023","journal-title":"Lancet Neurol."},{"issue":"10","key":"10.1016\/j.msard.2023.104826_bib0027","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1001\/archneur.1989.00520460115022","article-title":"The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus","volume":"46","author":"Krupp","year":"1989","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.msard.2023.104826_bib0028","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.msard.2023.104826_bib0029","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s40273-014-0167-5","article-title":"A review of the psychometric properties of generic utility measures in multiple sclerosis","volume":"32","author":"Kuspinar","year":"2014","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.msard.2023.104826_bib0030","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/nrneurol.2012.168","article-title":"Progressive multiple sclerosis: pathology and pathogenesis","volume":"8","author":"Lassmann","year":"2012","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2023.104826_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102724","article-title":"Disability measurement in Multiple Sclerosis patients 55 years and older: what is the expanded disability status scale really telling clinicians?","volume":"49","author":"Lynch","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104826_bib0032","article-title":"The impact of modifiable risk factors on lesion burden in patients with early multiple sclerosis","volume":"39","author":"Lorefice","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104826_bib0033","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.msard.2018.10.011","article-title":"Assessing the burden of vascular risk factors on brain atrophy in multiple sclerosis: a case- control MRI study","volume":"27","author":"Lorefice","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104826_bib0034","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2023.1076421","article-title":"Omics approaches to understanding the efficacy and safety of disease-modifying treatments in multiple sclerosis","volume":"14","author":"Lorefice","year":"2023","journal-title":"Front. Genet."},{"key":"10.1016\/j.msard.2023.104826_bib0035","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1212\/WNL.46.4.907","article-title":"Defining the clinical course of multiple sclerosis: results of an international survey","volume":"46","author":"Lublin","year":"1996","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.msard.2023.104826_bib0036","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.104826_bib0037","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S1474-4422(14)70256-X","article-title":"Pathological mechanisms in progressive multiple sclerosis","volume":"14","author":"Mahad","year":"2015","journal-title":"Lancet Neurol."},{"issue":"13","key":"10.1016\/j.msard.2023.104826_bib0039","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1212\/WNL.0b013e3181d6b125","article-title":"Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis","volume":"74","author":"Marrie","year":"2010","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.msard.2023.104826_bib0040","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1177\/13524585221111675","article-title":"The value of patient-reported outcome measures for multiple sclerosis","volume":"28","author":"McGinley","year":"2022","journal-title":"Mult. Scler."},{"issue":"9","key":"10.1016\/j.msard.2023.104826_bib0042","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1136\/jnnp-2018-319190","article-title":"Cerebrospinal fluid neurofilament light chain in multiple sclerosis and its subtypes: a meta-analysis of case-control studies","volume":"90","author":"Martin","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"3","key":"10.1016\/j.msard.2023.104826_bib0043","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.msard.2023.104826_bib0044","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/acn3.51732","article-title":"Real-world evaluation of ocrelizumab in multiple sclerosis: a systematic review","volume":"10","author":"Montalban","year":"2023","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.msard.2023.104826_bib0045","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S1474-4422(14)70264-9","article-title":"Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives","volume":"14","author":"Ontaneda","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2023.104826_bib0046","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2023.0717","article-title":"Incorporating the central vein sign into the diagnostic criteria for multiple sclerosis","author":"Ontaneda","year":"2023","journal-title":"JAMA Neurol."},{"issue":"1\u20132","key":"10.1016\/j.msard.2023.104826_bib0047","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jns.2003.09.015","article-title":"Correlations between multiple sclerosis functional composite, expanded disability status scale and health- related quality of life during and after treatment of relapses in patients with multiple sclerosis","volume":"218","author":"Ozakbas","year":"2004","journal-title":"J. Neurol. Sci."},{"issue":"9139","key":"10.1016\/j.msard.2023.104826_bib69","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0140-6736(98)10039-9","article-title":"Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2023.104826_bib0049","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1471-2377-12-11","article-title":"Meningeal and cortical grey matter pathology in multiple sclerosis","volume":"12","author":"Popescu","year":"2012","journal-title":"BMC Neurol."},{"key":"10.1016\/j.msard.2023.104826_bib0050","doi-asserted-by":"crossref","DOI":"10.1080\/14737175.2020.1760846","article-title":"Current state-of-art of the application of serum neurofilaments in multiple sclerosis diagnosis and monitoring","author":"Preziosa","year":"2020","journal-title":"Expert Rev. Neurother."},{"issue":"4","key":"10.1016\/j.msard.2023.104826_bib0051","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/WCO.0000000000000946","article-title":"Central vein sign and iron rim in multiple sclerosis: ready for clinical use?","volume":"34","author":"Preziosa","year":"2021","journal-title":"Curr. Opin. Neurol."},{"issue":"8","key":"10.1016\/j.msard.2023.104826_bib0052","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1093\/brain\/awac111","article-title":"Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study","volume":"145","author":"Portaccio","year":"2022","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.msard.2023.104826_bib0053","doi-asserted-by":"crossref","first-page":"e1059","DOI":"10.1212\/NXI.0000000000001059","article-title":"Prognostic accuracy of NEDA-3 in long-term outcomes of multiple sclerosis","volume":"8","author":"Prosperini","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"2","key":"10.1016\/j.msard.2023.104826_bib0054","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/BF01537606","article-title":"The use of the center for epidemiologic studies depression scale in adolescents and young adults","volume":"20","author":"Radloff","year":"1991","journal-title":"J. Youth Adolesc."},{"issue":"1","key":"10.1016\/j.msard.2023.104826_bib0055","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s42466-022-00219-3","article-title":"Real-world evidence on siponimod treatment in patients with secondary progressive multiple sclerosis","volume":"4","author":"Regner-Nelke","year":"2022","journal-title":"Neurol. Res. Pract."},{"issue":"7","key":"10.1016\/j.msard.2023.104826_bib0056","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1007\/s12325-019-00958-x","article-title":"Multiple sclerosis performance test: technical development and usability","volume":"36","author":"Rhodes","year":"2019","journal-title":"Adv. Ther."},{"issue":"8","key":"10.1016\/j.msard.2023.104826_bib0057","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1080\/14737175.2020.1739524","article-title":"What role should spinal cord MRI take in the future of multiple sclerosis surveillance?","volume":"20","author":"Rocca","year":"2020","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.msard.2023.104826_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2023.107612","article-title":"Discontinuation of disease- modifying therapy in MS patients over 60 years old and its impact on relapse rate and disease progression","volume":"225","author":"Salavisa","year":"2023","journal-title":"Clin. Neurol. Neurosurg."},{"issue":"6","key":"10.1016\/j.msard.2023.104826_bib0059","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1177\/1352458516634871","article-title":"Aging and multiple sclerosis","volume":"22","author":"Sanai","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.104826_bib0060","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1177\/1352458517726592","article-title":"Defining active progressive multiple sclerosis","volume":"23","author":"Sellebjerg","year":"2017","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2023.104826_bib0061","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/1352458507080733","article-title":"Validation of the multiple sclerosis international quality of life questionnaire","volume":"14","author":"Simeoni","year":"2008","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.msard.2023.104826_bib0062","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/WCO.0000000000000811","article-title":"The window of opportunity for treatment of progressive multiple sclerosis","volume":"33","author":"Sorensen","year":"2020","journal-title":"Curr. Opin. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2023.104826_bib0063","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/acn3.795","article-title":"Blood neurofilament light as a potential endpoint in Phase 2 studies in MS","volume":"6","author":"Sormani","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.msard.2023.104826_bib0064","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s004150050204","article-title":"Multiple sclerosis: assessment of disability and disability scales","volume":"245","author":"Thompson","year":"1998","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2023.104826_bib0065","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF02260859","article-title":"A health-related quality of life measure for multiple sclerosis","volume":"4","author":"Vickrey","year":"1995","journal-title":"Qual. Life Res."},{"issue":"4","key":"10.1016\/j.msard.2023.104826_bib0066","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/ana.25313","article-title":"Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial","volume":"84","author":"Wolinsky","year":"2018","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2023.104826_bib0067","article-title":"Multiple sclerosis versus cerebral small vessel disease in MRI: a practical approach using qualitative and quantitative signal intensity differences in white matter lesions","author":"Yuzkan","year":"2023","journal-title":"Acta Radiol."},{"issue":"6","key":"10.1016\/j.msard.2023.104826_bib0068","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr. Scand."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823003280?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823003280?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:07:49Z","timestamp":1761901669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034823003280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":66,"alternative-id":["S2211034823003280"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.104826","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How to measure the treatment response in progressive multiple sclerosis: Current perspectives and limitations in clinical settings\u2019","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.104826","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104826"}}